



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/786,135	06/25/2001	Y. Tom Tang	PF-0585 USN	5219

7590 10/15/2003

Incyte Genomics Inc  
Legal Department  
3160 Porter Drive  
Palo alto, CA 94304

EXAMINER

MERTZ, PREMA MARIA

ART UNIT	PAPER NUMBER
----------	--------------

1646

DATE MAILED: 10/15/2003

8

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/786,135

Applicant(s)

TANG ET AL.

Examiner

Prema M Mertz

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 28 July 2003.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 21-40 is/are pending in the application.
- 4a) Of the above claim(s) 30,32-34 and 37-40 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 21,23,26-28 and 35 is/are rejected.
- 7) ☒ Claim(s) 22,24,25,29 and 36 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All   b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                  | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)         | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____                                    |

**DETAILED ACTION**

Claims 1-20 have been canceled previously. Claims 21-40 (Paper No. 7 (7/28/03)) are pending in the instant application.

***Election/Restriction***

1. Applicant's election with traverse of Group II (claims 23-29 and 31) drawn to a nucleic acid encoding a protein of amino acid sequence of SEQ ID NO:1, a vector, a host cell and a process for producing the protein, in Paper No. 7 (7/28/03) is acknowledged. The traversal is on the ground(s) that the lack of unity is improper since the examiner has not shown that examination of the major inventions of Groups 1 and 2 would entail a serious burden. Upon further consideration and finding Applicants arguments persuasive, the protein of Group I and the polynucleotide of Group II will be examined together. Therefore, claims 21-29, 31 and 35-36 will be examined in the instant application.

Applicants argue that neither the full-length polypeptide or fragments thereof are disclosed in the reference. However, Claim 21 encompasses "biologically active fragments" which in the absence of recitation of a biological activity of the polypeptide, encompasses a single amino acid. Therefore, the polypeptide of the reference anticipates the "fragment" limitation of the instant claims.

Applicants request examination of the subject matter of the non-elected process claims 32-34 and claims 39-40 (see In re Ochiai (37 USPQ2d 1127 (Fed. Cir. 1995))), in which a new, unobvious material is used in a known process. Ochiai determined that a process was free of the prior art if it employed a product which was free of the prior art. However, only if the product claims of examined Groups I-II are found allowable, the subject matter of the claimed product will be rejoined with the process claims, if the process claims are of the same scope as the

Art Unit: 1646

allowable product claims (insofar as the new claims do not precipitate new rejections). Therefore, claims drawn to a method of using the polypeptide and polynucleotide will be rejoined with these products are found allowable.

Claims 30, 32-34, 37-40 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

***Specification***

2. This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

***Claim Rejections - 35 USC § 112, first paragraph***

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3a. Claims 21, 23, 26-28, 35 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The written description in this case only sets forth a polypeptide of SEQ ID NO:1 and equivalent degenerative codon sequences thereof and therefore the written description is not commensurate in scope with the claims drawn to “naturally occurring” protein variants of at least 90% identity to SEQ ID NO:1 as recited for example in claim 21(b)..

*Vas-Cath Inc. V. Mahurkar*, 19 USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was

Art Unit: 1646

in possession *of the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116).

Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 USC 112 is severable from its enablement provision (see page 115).

Reiger et al (Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976) clearly define alleles as one of two or more alternative forms of a gene occupying the same locus on a particular chromosome..... and differing from other alleles of that locus at one or more mutational sites ( page 17). Thus, the structure of naturally occurring allelic sequences are not defined. With the exception of SEQ ID NO:41, the skilled artisan cannot envision the detailed structure of the encompassed polynucleotides and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and a reference to a potential method of isolating it. The nucleic acid itself is required. See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, 18 USPQ2d 1016.

Furthermore, In *The Regents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), the court held that a generic statement, which defines a genus of nucleic acids by only their functional activity does not provide an adequate written description of the genus. The court indicated that while Applicants are not required to disclose every species encompassed by a genus, the description of a genus is achieved by the recitation of a representative number of

Art Unit: 1646

DNA molecules, usually defined by a nucleotide sequence, falling within the scope of the claimed genus. At section B(1), the court states that “An adequate written description of a DNA...’requires a precise definition, such as by structure, formula, chemical name, or physical properties’, not a mere wish or plan for obtaining the claimed chemical invention”.

Support for allelic variants is provided in the specification on pages 4 and 12 of the instant specification. However, no disclosure, beyond the mere mention of variants is made in the specification. This is insufficient to support the generic claims as provided by the Interim Written Description Guidelines published in the June 15, 1998 Federal Register at Volume 63, Number 114, pages 32639-32645.

Therefore only an isolated nucleic acid molecule comprising a nucleic acid sequence consisting of SEQ ID NO:2 and a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 and equivalent degenerative codon sequences thereof, but not the full breadth of the claims meets the written description provision of 35 USC 112, first paragraph.

3b. Claims 21, 23, 26-28, 35 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated polynucleotide encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 and the polypeptide encoded thereby, does not reasonably provide enablement for an isolated a naturally occurring polynucleotide at least 90 % identical to SEQ ID NO:2 or an isolated a naturally occurring polypeptide at least 90 % identical to SEQ ID NO:1. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Art Unit: 1646

Claim 21, for example, is overly broad in the recitation of "at least 90% identical to an amino acid sequence" since no guidance is provided as to which of the myriad of polypeptide species encompassed by the claim will retain the desired characteristics. Applicants disclose that variants of the polynucleotide can be generated by conservative or nonconservative changes, allelic, splice species or polymorphic variants, arising by natural deletions additions or substitutions, without disclosing any actual or prophetic examples on expected performance parameters of any of the possible muteins of SEQ ID NO:1 (page 4, lines 27-33). There is no guidance provided in the specification as to how one of ordinary skill in the art would generate a nucleic acid sequence encoding a polypeptide other than that exemplified in the specification. See *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404. The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue. The factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue" include, but are not limited to: (1) the breadth of the claims; (2) the nature of the invention; (3) the state of the prior art; (4) the level of one of ordinary skill; (5) the level of predictability in the art; (6) the amount of direction provided by the inventor; (7) the existence of working examples; and (8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. Given the breadth of the claims in light of the predictability of the art as determined by the number of working examples, the level of skill of the artisan, and the guidance provided in the instant specification and the prior art of record, it would require undue experimentation for one of ordinary skill in the art to make and use the claimed invention.

Art Unit: 1646

***Claim rejections-35 USC § 112, second paragraph***

4. Claims 21, 23, 26-28, 31, 35 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 21, 31 are indefinite in the recitation of the term "naturally occurring". It is unclear whether this term imposes a required limitation on the claim, such that it only encompasses, for example, nucleic acid molecules amplified from cDNA or all nucleic acid molecules that encode the polypeptide. Therefore, the metes and bounds of the claim are unclear.

Claim 21 is rejected for reciting "biologically active fragment". It is unclear what the metes and bounds of this limitation are because a single amino acid encompasses a "biologically active fragment" and meets the limitations of this claim. Recitation of the biological activity of fragment in the claim would obviate this rejection.

Claim 21 is rejected as vague and indefinite for reciting "immunogenic fragment". It is unclear what the metes and bounds of this term are. It is suggested that the claim be amended to incorporate the size of the specific immunogenic fragments supported by the specification.

Claims 23, 26-28, 35 are rejected as vague and indefinite insofar as they depend on the above rejected claims for their limitations.

***Claim Rejections - 35 USC § 102***

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –



Art Unit: 1646

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 21 and 23, are rejected under 35 U.S.C. 102(b) as being anticipated by Morgan et al (1996).

The reference discloses a cDNA encoding a LIM-protein expressed in skeletal muscle, SLIM (see abstract, page 632; page 635, Figure 2). A biologically active fragment of the polypeptide of the reference, would potentially be any amino acid. Therefore, the cDNA and polypeptide disclosed in the reference meets the limitations of claims 21, 23.

***Claim rejections-35 USC § 103***

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 26-28, 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan et al (1996).

The disclosure of Morgan et al. has been set forth above in paragraph 6. However, Morgan never produced the protein recombinantly by using the polynucleotide. It would have been *prima facie* obvious to one of ordinary skill in the art at the time the instant invention was made to place the polynucleotide encoding the SLIM protein, in an expression vector and host cell which expresses the protein encoded thereby, and recovering the recombinant protein produced to study the biochemical properties of the protein. To have incorporated the recombinant polynucleotide encoding the protein identified as SLIM by Morgan et al, into an expression vector and host cell to facilitate the production and characterization of the protein encoded thereby by employing those methods that were old and well known in the art of

Art Unit: 1646

molecular biology at the time that the instant invention was made would have been *prima facie* obvious to an artisan in light of the Morgan publication. Furthermore, it would have been obvious to one of ordinary skill in the art at the time that the invention was made, to merely admix a carrier with a protein i.e. the protein, and obtaining such does not render the resulting composition patentable if it would have been obvious to formulate the protein with a pharmaceutically acceptable carrier relative to its art intended use (In re Rosicky 125 USPQ 341).

**Conclusion**

No claim is allowable.

Claims 22, 24, 25, 29, 36, are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form.

**Advisory Information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (703) 308-4229. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 305-3014 or (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 746-5300.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark Office on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

  
Prema Mertz Ph.D.  
Primary Examiner  
Art Unit 1646

Application/Control Number: 09/786,135

Page 10

Art Unit: 1646

October 4, 2003